Breast Cancer Radiotherapy Market Size, Share, and Growth Forecast 2026 - 2033

The global breast cancer radiotherapy market size is likely to be valued at US$36.7 billion in 2026 and is estimated to reach US$74.2 billion by 2033, growing at a CAGR of 10.6% during the forecast period from 2026 to 2033, driven by the rising global breast cancer burden and surging use of radiotherapy in breast-conserving treatment. The shift toward hypofractionated and short treatment schedules is improving treatment efficiency and expanding the role of advanced radiotherapy systems.

Driver - Breast-conserving Surgery to Propel the Need for Radiotherapy

The continued use of breast-conserving surgery is supporting demand for postoperative radiotherapy. Lumpectomy removes the visible tumor while leaving most of the breast intact. Radiation is then used to reduce the risk of cancer returning in the remaining breast tissue. This makes radiotherapy an important part of breast-conserving treatment rather than an optional add-on. NCI identifies radiation therapy as part of breast-conserving therapy, particularly after lumpectomy. The continued refinement of breast-conserving approaches is also creating demand for precise treatment planning, image guidance, and techniques that protect the heart and lungs.

The trend is also expanding the role of shorter treatment schedules. Modern breast radiotherapy can often be delivered using hypofractionation, which reduces the number of treatment sessions while maintaining effective local control for appropriate patients. The 2025 ASTRO/ASCO/SSO guideline on postmastectomy radiation therapy states that moderate hypofractionation is generally preferred when postmastectomy radiation is indicated. It also recommends CT-based planning, with IMRT, daily image guidance, and deep-inspiration breath hold used where appropriate.

Rising Incidence of Breast Cancer to Broaden Patient Pool

The rising number of breast cancer cases is creating a larger pool of patients who may require radiation as part of multimodal treatment. The WHO estimates that 2.4 million women were diagnosed with breast cancer and 694,000 died from the disease in 2024. Breast cancer was the most common cancer among women in 164 of 186 countries that year.

This burden is particularly important for radiotherapy as treatment is often combined with surgery and systemic therapy. Improvements in early detection can also increase the number of patients diagnosed at stages where curative treatment is possible. The WHO's Global Breast Cancer Initiative focuses on early detection, timely diagnosis, and comprehensive treatment. As more countries strengthen these pathways, demand can shift from basic cancer care toward complete treatment programs that include radiotherapy.

Restraint - Specialist Shortages May Limit Radiotherapy Capacity

Limited availability of trained radiation specialists can slow the expansion of breast radiotherapy services, particularly in emerging markets. Modern treatment requires coordinated work by radiation oncologists, medical physicists, dosimetrists, radiation therapists, engineers, and other specialists. The IAEA reports major workforce gaps across income groups, with particularly low coverage among lower-middle- and low-income countries. Its data show medical-physicist coverage at only 20.4% in lower-middle-income countries and 5.4% in low-income countries relative to estimated need.

The shortage also affects adoption of advanced technologies. MRI-guided, adaptive, image-guided, and highly automated systems require specialized training and quality assurance. The IAEA notes that low- and middle-income countries often have too few medical physicists qualified to supervise training and advanced radiotherapy programs. This can delay equipment commissioning and limit the number of patients who can benefit from sophisticated treatment approaches.

Opportunity - Surface Guidance to Enable More Patient-friendly Treatment

Surface-guided radiation therapy is creating an opportunity for tattoo-free breast radiotherapy and more automated patient positioning. Traditional breast radiotherapy often uses permanent skin marks to help reproduce the patient's position during treatment. SGRT instead uses optical surface imaging to track the patient's body position in real time.

Recent clinical evidence is strengthening this opportunity. A 2025 study of 30 patients receiving whole-breast radiotherapy evaluated a tattoo-free SGRT setup and found that 95.8% of treatment fractions were within the predefined 0.5-cm tolerance. Among imaged fractions, 98% of patients were positioned within 0.5 cm of the treatment isocenter, compared with 80% using the conventional tattoo-alignment approach in the comparison group.

Adaptive Radiotherapy to Help Support Personalized Treatment

Adaptive radiotherapy offers an opportunity to adjust treatment according to changes in patient anatomy during the treatment course. Breast shape, swelling, weight, positioning, and other anatomical factors can change during several weeks of treatment. Advanced imaging and treatment-planning systems can help identify these changes and determine whether treatment needs to be modified.

This creates an opportunity for vendors to combine imaging, artificial intelligence, treatment planning, and radiation delivery into integrated platforms. The 2025 ASTRO/ASCO/SSO guideline already emphasizes CT-based volumetric planning and daily image guidance for appropriate postmastectomy cases. As imaging and automated planning become more sophisticated, these capabilities can support more individualized treatment workflows.

Therapy Type Insights

External Beam Radiation Therapy (EBRT) is predicted to lead with a share of about 65.8% in 2026, as it can treat the whole breast, chest wall, or selected breast tissue from outside the body and can be delivered on an outpatient basis. NCI identifies EBRT and brachytherapy as the two main radiation approaches for breast cancer and notes that EBRT is commonly delivered as an outpatient treatment. Its compatibility with LINACs, IMRT, IGRT, hypofractionation, and breath-hold techniques also makes it adaptable to different disease and patient requirements.

Another important factor is its broad applicability after breast-conserving surgery and in selected postmastectomy cases.

Internal radiation therapy (brachytherapy) is estimated to be the fastest-growing type over the forecast period, as it places the radioactive source close to the tumor bed, allowing radiation to be concentrated in a smaller treatment area. This is particularly relevant for selected early-stage patients receiving partial-breast irradiation. ASTRO's guideline recognizes multicatheter interstitial brachytherapy as one of the recommended techniques for partial-breast irradiation in appropriately selected patients. Its role is hence becoming more specialized rather than simply replacing EBRT.

Brachytherapy can support short, localized treatment courses and may reduce radiation exposure to surrounding tissue when used in suitable patients.

Treatment Type Insights

Whole-breast irradiation is anticipated to dominate with a share of around 44.3% in 2026, as it provides broad coverage of the breast after breast-conserving surgery and has an established evidence base for reducing local recurrence. NCI states that whole-breast radiation uses an external X-ray machine to treat the entire breast, while ASTRO has maintained dedicated clinical guidance covering whole-breast fractionation, treatment techniques, and tumor-bed boosts. Its use is also supported by the large number of patients undergoing breast-conserving treatment.

Radiation is an important component of breast-conserving therapy as surgery removes the visible tumor while radiation addresses residual microscopic disease in the treated area.

Partial-breast irradiation is expected to be the fastest-growing treatment type over the forecast period, as evidence now supports treating selected early-stage patients effectively with a smaller radiation field and fewer treatment visits. ASTRO's 2023 guideline found comparable outcomes between partial- and whole-breast radiation in several randomized trials and strongly recommends partial-breast irradiation as an alternative for appropriately selected patients with favorable features. The treatment is also attractive as it fits the broader shift toward shorter and more targeted radiotherapy. ASTRO recommends daily or every-other-day partial-breast treatment rather than twice-daily schedules.

North America Breast Cancer Radiotherapy Market Trends

North America is predicted to dominate in 2026 globally with a share of approximately 40.5%, as it combines mature radiotherapy infrastructure, strong cancer-center networks, widespread access to advanced treatment technologies, and a well-established clinical research environment. The U.S. alone has thousands of radiotherapy centers recorded in the IAEA's DIRAC database, while NCI-designated cancer centers provide access to advanced cancer treatment and research.

The region also has strong adoption of modern breast radiotherapy approaches such as hypofractionation, IMRT, image guidance, and partial-breast irradiation. ASTRO's clinical guidelines have helped establish evidence-based pathways for these approaches.

U.S. Breast Cancer Radiotherapy Market Trends

A share of nearly 68.2% is expected to be held by the U.S. in 2026 in North America, owing to its large breast cancer patient population, extensive radiation-oncology infrastructure, and rapid adoption of shorter and more personalized treatment approaches. Breast cancer is the most common malignancy treated with radiation therapy in the U.S., according to ASTRO. The country also has a large network of NCI-designated cancer centers and community radiotherapy facilities.

The shift toward hypofractionation is particularly important. A 2024 analysis of more than one million U.S. patients who underwent lumpectomy found that hypofractionated whole-breast irradiation increased sharply over time and had become standard care by 2020.

Asia Pacific Breast Cancer Radiotherapy Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026 with a share of around 25.8%, as breast cancer incidence is rising alongside improvements in cancer screening, diagnosis, treatment infrastructure, and access to radiotherapy. The region also has large populations that create substantial unmet demand for radiation services. The IAEA continues to support expansion of radiotherapy capacity in countries where equipment and trained specialists remain limited. Governments are also investing in advanced oncology infrastructure.

China Breast Cancer Radiotherapy Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 39.5%, as its large breast cancer burden is being matched by continued expansion of advanced oncology infrastructure and radiotherapy equipment. China's National Health Commission issued approvals for high-end radiotherapy equipment in 2025 and planned additional installations of high-end radiotherapy systems and heavy-ion/proton therapy systems under its medical-equipment allocation program.

Japan Breast Cancer Radiotherapy Market Trends

In 2026, Japan is projected to account for a share of just about 26.7% in Asia Pacific, as its national cancer strategy continues to prioritize radiation therapy, advanced medical technologies, workforce development, and digitalization. Japan's Fourth-term Basic Plan for Cancer Control includes surgery, radiation therapy, drug therapy, team-based care, new medical devices, human-resource development, and digitalization as key elements of cancer care.

Europe Breast Cancer Radiotherapy Market Trends

Europe will likely witness steady growth over the forecast period with a share of roughly 15.5% in 2026 globally, as it has established cancer-screening programs, developed radiotherapy networks, and broad use of evidence-based breast-conserving treatment. The region also has strong professional organizations and clinical research networks that support the adoption of hypofractionation, partial-breast irradiation, image guidance, and other precision techniques.

Germany Breast Cancer Radiotherapy Market Trends

Germany is predicted to register a substantial share of approximately 33.7% in 2026 in Europe, supported by established oncology infrastructure, evidence-based radiotherapy, and increasing use of shorter treatment schedules. German national breast cancer guidance supports moderate hypofractionation for adjuvant whole-breast radiation and notes that shorter treatment can provide comparable tumor control with fewer treatment visits.

U.K. Breast Cancer Radiotherapy Market Trends

A share of nearly 16.5% is predicted to be held by the U.K. in 2026 in Europe, as the NHS continues to emphasize shorter radiotherapy courses, efficient treatment delivery, and evidence-based breast cancer care. The shift toward hypofractionation is particularly relevant as shorter schedules can reduce hospital visits and increase treatment capacity. The broader U.K. adoption of evidence-based hypofractionated breast radiotherapy also creates demand for LINACs, treatment-planning systems, image guidance, and surface-guided positioning.

The global breast cancer radiotherapy market is moderately consolidated, with a small group of large radiotherapy technology companies competing alongside specialized software, imaging, surface-guidance, brachytherapy, and particle-therapy providers. The strongest competition is concentrated around linear accelerators, treatment-planning software, image guidance, adaptive radiotherapy, and precision patient positioning. Companies are competing on the complete treatment workflow rather than on the radiation-delivery machine alone.

Siemens Healthineers through Varian, Elekta, Accuray, IBA, Brainlab, RaySearch Laboratories, and other technology providers have established positions across different parts of this ecosystem. The IAEA's DIRAC database tracks more than 8,500 radiotherapy centers and more than 20,000 radiotherapy units across more than 150 countries, highlighting the broad installed base that supports this competitive environment. Competition is also shifting toward short treatment schedules, better imaging, automated planning, and non-invasive patient positioning.

Key Industry Developments:

• In May 2026, ASTRO and ESTRO announced a formal agreement to collaborate on future radiation-oncology clinical guidelines. The memorandum of understanding established a framework for the two organizations to jointly develop most future guidelines, supporting greater alignment in evidence-based radiation-treatment recommendations across the U.S. and Europe.
• In May 2026, RaySearch reported the first clinical use of online adaptive radiotherapy with RayStation and RayCare on a Varian TrueBeam system at Belgium's Iridium Network. The workflow uses daily imaging, deep-learning segmentation, and automated treatment-plan optimization to adapt radiation delivery to changes in patient anatomy, demonstrating the movement of adaptive radiotherapy toward routine clinical workflows.
• In May 2026, Leo Cancer Care and Chabner XRT announced a strategic collaboration to advance upright radiotherapy for breast cancer. The companies plan to evaluate the integration of Leo Cancer Care's upright treatment platform with Chabner XRT's FDA-cleared radiotherapy bra to improve patient positioning, treatment reproducibility, and protection of organs such as the heart and lungs.